×öʲô¶¼Òª³ÃÔçµÄÄêÇáÈË£¬Èç½ñÉú²¡Ò²³ÃÔçÁË¡£¸ÐðͷÔÎÊÇÀÏÅóÓÑ£¬³¦Î¸²»ÊÊÊǼҳ£±ã·¹£¬Á¬±¾Ó¦´¦ÓÚÍêÃÀ״̬µÄ¹Ø½Ú£¬Ò²¿ÉÄÜÀÏ쾯±¨£¬ÀýÈçÒ»Ö±±»ÈÏΪÊÇ¡°ÀÏÄ겡¡±µÄÍ´·çÒѾ¶¢ÉÏÄêÇáÈË¡£Ô¸ÃÊÇ»î±ÄÂÒÌøµÄÄê¼Í£¬Ò»Åú¶þÊ®¶àËêµÄ´àƤСÇàÄêÈ´°ëҹʹÐÑ£¬Îæ×Å´ó½ÅÖº£¬ÔÚÇë¼ÙÌõÉÏдÏÂÀíÓÉ¡°Í´·ç¡±¡£ÒÔÍù³Ô¡°Í´·çÌײ͡±ºÁÎÞ¸ºµ£µÄÄêÇáÈË£¬¿ªÊ¼¶Ôº£ÏÊÆ¡¾Æ¾´Ð»²»Ãô£¬ÉúÅÂÄòËáÒ»ÑÔ²»ºÏ¾ÍÉý¸ß£¬Í´µÃϲ»ÁË´²Ê±Óû¿ÞÎÞÀá¡£Ô½À´Ô½¶àÄêÇáÈË£¬ÊÜÍ´·çÕÛÄ¥ÒÔÇ°£¬¶þÊ®À´ËêµÄÈË¿ÖÅ·ֲ»Çå·çʪÓëÍ´·ç£¬ÒòΪ²¡²»ÔÚ×Ô¼ºÉíÉÏ£¬¶¥¶àÖ»ÖªµÀ¶¼ÊǹؽÚÍ´¡£2019Äêʱ£¬Äê½ö23ËêµÄ¹ù÷è÷ë¼×ÛÒÕ¡¶ÂþÓμǡ·Í´·ç·¢×÷µ½×øÂÖÒεij̶ȣ¬¸øÁ˹ÛÖÚһЩССµÄÕ𺳣ºÔõôÕâôÄêÇᣬҲ»áµÃÍ´·ç£¿Í´·ç£¬Ôø¾±»³ÆΪ¡°µÛÍõ²¡¡±£¬ÔڹŴúÊÇÑø×ð´¦Óŵĸ»¹óÖ®È˲ŻáµÃµÄº±¼û²¡¡£µ«Ëæ×Å´ó¼ÒÉú»îÌõ¼þ¸ÄÉÆ£¬Í´·çµÄÈËÒ²Ô½À´Ô½¶à£¬´Ó1990Äêµ½2019Ä꣬ȫ¹úÍ´·ç»¼Õß´Ó586ÍòÈËÔö¼ÓÖÁ1616ÍòÈË [1]¡£Ñ§ÊõÒ»µãÀ´Ëµ£¬Í´·çÊÇѪÖÐÄòËẬÁ¿¹ý¸ß¶øµ¼ÖÂÄòËáÑνᾧ³Á»ýÔڹؽÚÄڵļ²²¡ [2]¡£¸ßÄòËáѪ֢ÊÇÆäÁÙ´²Ç°ÆÚ±íÏÖ [3]£¬´Ó¸ßÄòËáѪ֢µÄÈ«¹úÐÔµ÷²éÊý¾Ý¿´£¬ÄòËáÆ«¸ßµÄÄêÇáÈËÒ²Ô½À´Ô½¶à¡£Öйú¼²¿ØÖÐÐĵÄÖйúÂýÐÔ²¡¼°Î£ÏÕÒòËؼà²âϵͳ£¨CCDRFS£©ÔÚ2015ÄêºÍ2018Äê¸÷Õ¹¿ªÁËÒ»´ÎÈ«¹úµ÷²é£¬2015ÄêÊý¾ÝÏÔʾ18ËêÒÔÉÏÈËȺÖл¼ÓиßÄòËáѪ֢µÄ±ÈÀýÊÇ11.1%£¬ÈýÄêºóÕâ¸ö±ÈÀýÉÏÉýµ½ÁË14% [4]£¬ÉÏÒÚÈËÊܵ½Ó°Ïì¡£18-29ËêÄêÇáÈ˵ĸßÄòËáѪ֢»¼²¡ÂÊ£¬¸üÊÇ´Ó13.4% ÉÏÉýÖÁ18%£¬ÕÇ·ù´ï34%¡£ÕâЩ²»µ½30ËêµÄ¸ßÄòËáÄêÇáÈËÈç¹ûÍ´·ç·¢²¡£¬ÔÚҽѧÉϻᱻÈÏΪÊÇÔç·¢ÐÔÍ´·çÈËȺ£¬¶øÔç·¢ÐÔÍ´·ç¸üÈÝÒ׳öÏÖ¸ÎÉö¹¦ÄÜÎÊÌâ [5]¡£Ïñº£ÏʱéµØµÄÇൺ£¬×ÔÈ»ÄÑÌÓ³ÉΪʹ·ç¸ß·¢µØµÄÃüÔË¡£Ò»ÏîÕë¶ÔÇൺ½üÍòÃûÍ´·ç»¼ÕßµÄÑо¿Ö±½ÓչʾÔç·¢ÐÔÍ´·ç²¡ÀýÔö¼Ó¡¢Í´·çÏÔÏÖÄêÇữµÄÇ÷ÊÆ£º2008-2012Äê¼ä¾ÍÕïµÄÍ´·ç»¼ÕßÊ״η¢²¡Æ½¾ùÄêÁäΪ46Ë꣬ÆäÖÐÔç·¢ÐÔ±ÈÀýΪ11.7%£¬µ½2013-2018Äê¼äÊ״η¢²¡Æ½¾ùÄêÁä¾ÍϽµµ½41.9Ë꣬Ôç·¢ÐÔ±ÈÀýÒ²·±¶ÖÁ23.7% [6]¡£Õâ¸öÑо¿¿ÎÌâµÄ×÷ÕßÖ®Ò»À¹ó½ÌÊÚÌáµ½Çé¿ö»¹ÔÚ±äµÃ¸üÔ㣬Çൺ´óѧ¸½ÊôÒ½Ôº½üÄêÿÄê½ÓÕïµÄÁ½Íò¶àÃûÍ´·ç²¡ÈËÖУ¬Ô¼Èý·ÖÖ®Ò»µÄ»¼Õ߶¼ÊÇÔÚ30ËêÇ°·¢²¡¡£Ëû½ÓÕï¹ýµÄСµÄÍ´·ç»¼ÕßÄêÁä¿ÉÄܳ¬ºõÄãÏëÏ󡪡ªÄÇÊÇÒ»Ãû½öÓÐ11ËêµÄÌåÐÍÆ«ÅÖµÄСÄк¢£¬¾ÍÕïʱ¹Ø½ÚÖ×ÕÍÁË20¶àÌì [7]¡£ÄѹÖÏÖÔÚÓеÄÄêÇáÈË£¬ÌرðÊÇÓÐÄòËá¸ßÇ°¿ÆµÄÄêÇáÈË£¬ÊÕµ½Äê¶ÈÌå¼ì±¨¸æµÄʱºò£¬³ýÁ˹Ø×¢Éí¸ßÓÐûÓдÜÒ»´Ü¡¢ÌåÖØÓÐûÓвä²äÉÏÕÇÍ⣬»¹¶îÍâ¹Ø×¢ÄòËáÕâ¸öÖ¸±êÊÇ·ñ¿ç¹ýÁË¡°420¦Ìmol/L¡±µÄ¾¯½äÏß¡£Äê¼ÍÇáÇáµÄ£¬Ôõô¾ÍÍ´·çÁ˺ö˶˵أ¬ÄòËáÔõô¾ÍÉý¸ßÁËÄØ£¿¿ÉÒÔÀ´»Ø¹ËһϸßÖÐÉúÎï֪ʶ£¬ÄòËáÊÇàÑßÊ´úлµÄ×îÖÕ²úÎï¡£ËùÒÔÄòËá¸ßÓëàÑßÊ´úлÎÉÂÒÓÐ×ÅĪ´ó¹Øϵ£¬àÑßÊÉãÈë¹ý¶àÒ²»áÔì³ÉÓ°Ïì¡£¾ÍÏñÌÇÄò²¡»¼Õß²»Ò˳ÔÉýÌǸߵÄʳÎï¡¢¸ßѪѹ»¼Õß²»Ò˳ÔÈÈÁ¿¸ßµÄ¶«Î÷£¬ÄòËá¸ßµÄÍ´·ç»¼ÕßÿÈÕÒûʳàÑßʺ¬Á¿½¨Òé¿ØÖÆ200mg ÒÔÏ [8]£¬ËûÃÇÒ²ÓÐ×Ô¼ºµÄʳÎïºìºÚ°ñ¡£¹ú¼ÒÎÀ½¡Î¯µÄ¡¶³ÉÈ˸ßÄòËáѪ֢ÓëÍ´·çʳÑøÖ¸ÄÏ¡·½«Ã¿100g º¬150mg ÒÔÉÏàÑßʵÄʳÎï»®¶¨Îª¸ßàÑßÊʳÎï [9]¡£°´Õâ¸ö±ê×¼£¬º£ÏÊÓÈΪΣÏÕ¡£Ïñ»î²ÝϺµÄàÑßʺ¬Á¿Îª719mg/100g [10]£¬Ò»Ö»Ò»Á½°Ù¿ËÖصIJÝϺÈë¿Ú£¬àÑßÊÉãÈëÁ¿Ö±½Ó´ó´ó³¬±ê¡£²»¹ýÔÚʵ¼ÊÉú»îÖУ¬´ó¶àÊýÈËÈÕ³£²Í×ÀÉÏ°ÚµÄÊÇÖíÅ£Ñò¼¦Ñ¼È⣬ÐóÇÝÈâÀàʳÎïÈÕ³£àÑßʹ±Ï×ÂÊÆäʵ²ÅÊÇ×î¸ß£¬ÄÜÊÇÓãϺз±´À๱Ï×ÂʵĽüÁ½±¶ [11]¡£¶øÔÚÐóÇÝÈâÀàÖУ¬ÓÈÆäÐèÒª¾¯Ìè¸ÎÔ࣬ÿ°Ù¿ËѼ¸Î¡¢¼¦¸Î¡¢Öí¸Î£¬àÑßʺ¬Á¿¶¼ÄÜì®ÉÏÁ½Èý°ÙºÁ¿Ë [10]¡£µ±È»£¬»¹ÓÐһЩ²»Ì«ÎªÈËÊìÖªµÄ¡°àÑßÊ´Ì¿Í¡±£¬ÀýÈç»Æ¶¹¡¢¾ú¹½ÕâЩüÇåÄ¿ÐãµÄÒæÖÇÇ¿ÉíʳƷ£¬àÑßʺ¬Á¿Ò²Óд󼸰ٺÁ¿Ë [10]£¬µ«²»Óüɿڣ¬ÖóºóÆúÌÀ³Ô¿É¼õÉÙàÑßÊÁ¿¡£²¡´Ó¿ÚÈë²»Ö¹ÊÇʳÎïµÄ¹ø£¬ÒûÆ·ÖÐÒ²ÓÐΣÏÕ·Ö×Ó£¬³ýÁËàÑßÊÍ⣬ÈéËáºÍ¹ûÌÇÒ²»áΪ»¢×÷Øö¡£¡°Í´·çÌײ͡±ÀﺣÏʵÄÁíÒ»°ë¡ª¡ª¾Æ£¬²»½ö»á´Ù½øÄòËáÉú³É£¬»¹»áÔÚÌåÄÚ´úлʱÁîÈéËáŨ¶ÈÉý¸ß£¬½ø¶øÒÖÖÆÁËÄòËáÅÅй [12]¡£±ðÒÔΪ¡°×øСº¢ÄÇ×À¡±µÄ²»ºÈ¾ÆÈËÊ¿¾ÍÄÜÔ¶Àë·çÏÕ£¬Èç¹ûÄã¶Ô·ÊÕ¬¿ìÀÖË®ÇéÓжÀÖÓ£¬ÄÇ¿ÖÅÂÒ²ÔÚ½ÙÄÑÌÓ£¬º¬ÌÇÈíÒû¡¢Ì¼ËáÒûÁÏ»áÔÚÌåÄÚ´úл³ö´óÁ¿¹ûÌÇ£¬´Ó¶øת»¯Îª¿ÉÒԺϳÉàÑßʵÄÎïÖÊ£¬Ê¹ÄòËáÉú³ÉÔö¶à [13]¡£³Ô·¹Òû¾ÆÒÔÍ⣬ʹ·çµÄÓÕ·¢ÒòËØ»¹Óв»ÉÙ£¬°üÀ¨ÀûÄò¼ÁÕâÀàÒ©ÎïºÍÌÇÄò²¡¡¢¸ßѪѹµÈÂýÐÔ²¡ [14]¡£¶ø¶ÔÓÚÏë±ÜÃâÍ´·çµÄÄêÇáÈËÀ´Ëµ£¬ÎüÑÌ¡¢¼Ò×åÊ·ºÍ´úл×ÛºÏÕ÷Õ⼸¸öΣÏÕÒòËظüÖµµÃ¾¯Ìè [15]¡£ÓÐЩÄêÇáÈËÒòΪÒÅ´«£¬²»ÐÒÔçÔçÍ´·ç£¬µ«Ò²Óв»ÉÙÄêÇáÈËÒòΪ·ÊÅÖ£¬´ó´óÌá¸ßÁËÍ´·çµÄ¡°Öн±¡±¼¸ÂÊ£¬¿ÉÒÔ˵ºú³Ôº£Èû¡¢°¾Ò¹¡¢ÀÁµÃÔ˶¯£¬ÕâЩÄêÇáÈËϲ°®µÄ¡¢Ò×ÅÖµÄÉú»î·½Ê½ÕýºÃ¶¼ÊÇÍ´·çµÄÀ×Çø [15]¡£ÄêÇáÈË·Å×ÝÉú»îʱ¾ÍÏñÈÓ³öÁËÒ»Ö§»ØÐýïÚ£¬¶øÍ´·ç·¢×÷¾ÍÊÇÕâÖ§»ØÐýïÚÔúÏòÁË×Ô¼º¡£Í´·çµ½µ×Óжà²Òһʱ·Å×Ýһʱˬ£¬Í´·ç·¢×÷»ðÔ᳡¡£µ±Í´·ç¼±ÐÔ·¢×÷µÄʱºò£¬µ½µ×ÓжàÍ´£¿Ç×Éí¾Àú¹ýµÄÈ˶¼º¬Àá»Ø´ð¡£w66¹ú¼Ê¡¤ÀûÀ´(Öйú)×î¸øÁ¦µÄÀÏÅÆ·ÖÎöÁËÖªºõºÍСºìÊéÉÏÍ´·ç»¼ÕߵľÀú£¬´ó²¿·ÖÈ˶¼»á´Ó´ó½ÅÖºµÄ¹Ø½Ú¿ªÊ¼£¬Æ½Ê±ºÁÎÞ´æÔڸеIJ¿Î»Í»È»·¢ÄÑ£¬ÕâÖÖÍ´¿à¿ÉÄÜһ·ÏòÉÏÂûÑÓµ½½Åõס¢Ï¥¸Ç¡£²¡Çé½ÏÖØʱ£¬Öⲿ¡¢ÊÖÍóÒ²ÔÚ½ÙÄÑÌÓ£¬ÊÖÖ¸Ò²Ïñ±»ÈÝæÖæÖÄÃÕëÔú¹ý¡£³ýÁËÍ´£¬»¹°éËæ¹Ø½ÚºìÖס¢·¢ÈÈ£¬Ö×ÈçÖíÌãµÄ½ÅÉì²»½øЬ×Ó£¬Í´µÃÁîÈËÖʱڷÖÀëµÄ¹Ø½ÚÖ§³Å²»×¡Õý³£ÐÐ×ß¡£¸ü±ÀÀ£µÄÊÇÍ´·ç×î°®°ëҹϮÀ´£¬ÓÐÈË˯ÃÎÖб»Ö±½Ó´ÌÐÑ£¬ÓÐÈËûÌÉϾͿªÊ¼ÔâÑ꣬×ÜÖ®Ôڹؽڡ°±»ÂìÒÏ¿Ðʳ¡±µÄÒ¹Íí£¬Ö»ÄÜÍû×ÅÌ컨°åÒ»Ò¹ÎÞÃß¡£¼±ÐÔÍ´·ç·¢×÷Èç»ðɽ±¬·¢£¬µÚÒ»´ÎÊÜÍ´·ç¶¾´òµÄÈËÐÄÀïÂúÊǺ¦ÅºÍÍ´¿à£¬ÕâÖÖÍ´¿à¾ÍËãÊÇÃÍÄÐÒ²Ö»ÄÜàÓàÓÂäÀᣬ¶ø¾Ã²¡µÄÈËÐÄÀï¸ü¶àÊÇÎÞ¾¡µÄµ£ÐÄÓëÕÛÄ¥¡£ÒòΪʹ·ç¿ØÖƲ»µ±¡¢·´¸´·¢×÷£¬»¹»áÑݱä³ÉÂýÐÔÍ´·ç¹Ø½ÚÑ×£¬ÉõÖÁ³öÏÖÍ´·çʯ³Á»ý [16]£¬ÊֽűäµÃ±È½Ó¹ÇľħÕÈ»¹»ûÐΡ£¸ü¿ÉŵÄÊÇËü»á¶ÔÉöÔàÓÐËùËðÉË£¬´úл²¡¡¢ÐÄѪ¹Ü¼²²¡µÈ²¢·¢Ö¢Ò²ÈÝÒ×ËæÖ®¶øÀ´ [17]¡£ÓÈÆäÊÇÐÄѪ¹Ü¼²²¡£¬ºÍÍ´·çµÄ¹²»¼ÂÊ´ïµ½74%-91% [18]£¬ÃÀ¹úÒ»ÏîÁ÷Ðв¡Ñ§µ÷²é½á¹ûÏÔʾ£¬Í´·ç»¼ÕßÖÐ74% ÓиßѪѹ£¬14% Óкϲ¢Ðļ¡¹£ËÀ [19]£¬¶øÇÒÍ´·ç·¢×÷ºó120ÌìÄÚ£¬ÐÄѪ¹Üʼþ»á¸üÈÝÒ×·¢Éú [20]¡£ÎªÁ˱ÜÃâÑÏÖصĺó¹û£¬ºÍËùÓÐÂýÐÔ²¡Ò»Ñù£¬Í´·çÐèÒªÒ©ÎïÊֶθ¨ÖúÖÎÁÆ¡£»¼ÓÐÍ´·çµÄÅóÓÑ¿ÉÄܶ¼ÖªµÀ£¬·¢×÷ʱÊÇ¿¿ÇïË®Ïɼîֹʹ¾ÈÃü£¬»º½âÆÚʱ¿¿·Ç²¼Ë¾Ëû½µÄòËáÐøÃü¡£µ«Ò©ÎïʼÖÕÊǾȻðÊֶΣ¬ÏëÒªÕæÕý¸ªµ×³éн£¬»¹µÃÊÇ¿¿½ÃÕý²»Á¼Éú»î·½Ê½¡£¡°¹Üס×ì¡¢Âõ¿ªÍÈ¡¢¶àºÈË®¡±¾Å×ÖÕæÑÔËäÈ»¿´ËÆ·º·º£¬µ«¶ÔÖÎÁÆÍ´·çÈ´Ò²ÐÐÖ®ÓÐЧ¡£µ±´úÄêÇáÈËȷʵ²»Ò×£¬¸ßѹµÄ¹¤×÷ѧϰѹ¿åÉíÌå¡¢·áÔ£µÄÎïÖʹ©¸ø·Å×ÝÉíÌ壬·ÀÓùÁ¦±¡ÈõµÄÇû¿Ç²»ÊDZ»Õâ¸ö²¡¶¢ÉϾÍÊDZ»ÄǸö²¡²øÉÏ¡£±»¸ÇÕÂΪ¡°´àƤ¡±µÄÄêÇáÈË£¬»¹ÊÇÒªÔçÔçÁìÎòÑøÉúµÄ¾«Ë裬ÄÄÅÂÊÇÅó¿ËÑøÉú£¬Ò²ÄÜÔÚ²¡Í´Ï®À´Ç°×¥½ô¸ø×Ô¼º¶àÌ×¼¸¸ö¶Ü¡£±¾ÎÄ¿ÆѧÐÔÒÑÓÉÅ®Íõ´óѧ²¡Àí¼°·Ö×Óҽѧ˶ʿÎéÀöÇàÉóºË²Î¿¼×ÊÁÏ£º[1] The Institute for Health Metrics and Evaluation. (2019). Global Burden of Disease. Retrieved December 14, 2023 from https://vizhub.healthdata.org/gbd-results.[2] Ĭɳ¶«ÕïÁÆÊÖ²á(´óÖڰ棩. (2022). Í´·ç. Retrieved December 14, 2023 from https://www.msdmanuals.cn/home/bone-joint-and-muscle-disorders/gout-and-calcium-pyrophosphate-arthritis/gout.[3] Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castaneda, J., Coyfish, M., Guillo, S., Jansen, T., Janssens, H., Liot¨¦, F., Mallen, C. D., Nuki, G., Perez-Ruiz, F., Pimentao, J., Punzi, L., Pywell, A., So, A. K., Tausche, A. K., Uhlig, T., ¡ Bardin, T. (2020). 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Annals of the rheumatic diseases, 79(1), 31¨C38.[4] Zhang, M., Zhu, X., Wu, J., Huang, Z., Zhao, Z., Zhang, X., Xue, Y., Wan, W., Li, C., Zhang, W., Wang, L., Zhou, M., Zou, H., & Wang, L. (2022). Prevalence of Hyperuricemia Among Chinese Adults: Findings From Two Nationally Representative Cross-Sectional Surveys in 2015-16 and 2018-19. Frontiers in immunology, 12, 791983.[5] ³ÂÀò»Ý, ³Â˼, Áõ·ç¾², µÈ. (2020). Ô緢ʹ·ç»¼ÕßµÄÁÙ´²ÌØÕ÷¼°Ïà¹ØÓ°ÏìÒòËØ·ÖÎö. ÖлªÄÚ·ÖÃÚ´úлÔÓÖ¾. 36(09) 767-772.[6] Gao, Q., Cheng, X., Merriman, T. R., Wang, C., Cui, L., Zhang, H., ... & Lu, J. (2021). Trends in the manifestations of 9754 gout patients in a Chinese clinical center: a 10-year observational study. Joint Bone Spine, 88(6), 105078.[7] Æë¾ê. (2021). ¹úÄÚ×îС»¼Õß11Ë꣡Çൺʹ·ç»¼Õß³¬30Íò Í´À´Èç·çÈçºÎ²øÉÏÄêÇáÈË. °ëµºÍø. Retrieved December 14, 2023 from https://news.bandao.cn/a/490103.html.[8] Öйúҽѧ»á. (2020). Í´·ç¼°¸ßÄòËáѪ֢»ù²ãÕïÁÆÖ¸ÄÏ£¨2019Ä꣩.[9] ¹ú¼ÒÎÀÉú½¡¿µÎ¯. (2023). ³ÉÈ˸ßÄòËáѪ֢ÓëÍ´·çʳÑøÖ¸ÄÏ£¨Òâ¼ûÕ÷Çó¸å£©.[10] ²Ì·êÀ,ÀäÀûƼ,²Ü°®Áá,л¾§,Àø½¨ÈÙ,ÉòÁÕ ÕÔÝÚ.(2018).ʳƷÖÐàÑßʺ¬Á¿·Ö²¼Ñо¿½øÕ¹.ʳƷ¿Æѧ¼¼Êõѧ±¨(05),74-81.[11] »Æ¼ÑÀÖ,ÍõÐÂÔ & ÀîºìÎÀ.(2019).ÏÃÃÅÊоÓÃñ¸ßÄòËáѪ֢ÓëÉÅʳàÑßÊÉãÈëµÄÏà¹ØÐÔÑо¿. ÓªÑøѧ±¨(01),20-23+29.[12] Àî²ý³¼. (1998). ¸ßÄòËáѪ֢ÓëÍ´·ç¸ßÄòËáѪ֢µÄ¶¨Òå¼°²¡ÐÍ·ÖÀà. ҽʦ½øÐÞÔÓÖ¾(06),3-4.[13] Àî»Û,ËÕÔÃ,ë´äÐã,ÀîÃ÷Õä ËïÀöÈÙ.(2016).º¬ÌÇÈíÒûÁÏÔÚÄêÇá·¢²¡Í´·ç»¼ÕßÖеÄ×÷ÓÃÑо¿.ÖйúÈ«¿Æҽѧ(18),2174-2178.[14] Singh, J. A., Reddy, S. G., & Kundukulam, J. (2011). Risk factors for gout and prevention: a systematic review of the literature. Current opinion in rheumatology, 23(2), 192¨C202.[15] Æëº,ѦÏþ÷,¼¾°®²ýµÈ. (2022). ɽ¶«Ê¡Í´·çÄêÇữÇ÷ÊƼ°Ïà¹ØΣÏÕÒòËØ·ÖÎö. ÖлªÄÚ·ÖÃÚ´úлÔÓÖ¾,38(5),375-381.[16] Ð춫, ÖìСϼ, ×޺ͽ¨, ÁÖºÌ,& ÕÔÑÒ. (2023). Í´·çÕïÁƹ淶. ÖлªÄÚ¿ÆÔÓÖ¾. 62(9)1068-1076.[17] Öì½£, ÕÔÒã, Ð춫, µÈ. (2018). Í´·çÏà¹Ø֪ʶÎÊ´ð£¨ËÄ£©£º²¢·¢Ö¢ºÍ°é·¢¼²²¡. ÖлªÄÚ¿ÆÔÓÖ¾, 57(12) : 930-931.[18] ÕÔÁ¦, ×޺ͽ¨, & ѦÓä. (2018). Í´·çÓëÐÄѪ¹Ü¼²²¡. ÖйúʵÓÃÄÚ¿ÆÔÓÖ¾, 38(12), 1131.[19] Zhu, Y., Pandya, B. J., & Choi, H. K. (2012). Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. The American journal of medicine, 125(7), 679-687.[20] Cipolletta, E., Tata, L. J., Nakafero, G., Avery, A. J., Mamas, M. A., & Abhishek, A. (2022). Association between gout flare and subsequent cardiovascular events among patients with gout. Jama, 328(5), 440-450.